{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-ide-specific-safety-reporting-and-device-deviations-21-cfr-812”
},
“headline”: “SOP for IDE-Specific Safety Reporting and Device Deviations (21 CFR 812)”,
“description”: “This SOP defines procedures for IDE-specific safety reporting and device deviation management under 21 CFR 812. It ensures timely reporting of unanticipated adverse device effects (UADEs), device malfunctions, and compliance with FDA requirements for investigational device studies.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for IDE-Specific Safety Reporting and Device Deviations (21 CFR 812)

Purpose

The purpose of this SOP is to define procedures for safety reporting and management of device deviations in clinical trials regulated under the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) regulations (21 CFR 812). It ensures that unanticipated adverse device effects (UADEs), device malfunctions, and deviations are reported and managed in compliance with regulatory timelines.

Scope

This SOP applies to sponsors, investigators, CROs, QA personnel, and regulatory affairs staff involved in IDE-regulated clinical investigations. It covers unanticipated adverse device effects, device malfunctions, deviations, IRB notifications, sponsor reports to FDA, and inspection readiness.

Responsibilities

• Sponsor: Submits UADE reports to FDA and IRB within required timelines and maintains deviation logs.
• Investigator: Reports all device-related SAEs and deviations to sponsor immediately.
• CRO: Assists in monitoring, reconciliation, and reporting activities.
• Regulatory Affairs: Prepares FDA submissions and maintains inspection readiness.
• QA: Audits safety reporting and device deviation records.

Accountability

The Sponsor’s Device Safety Officer is accountable for ensuring compliance with IDE safety reporting and deviation requirements. Investigators are accountable for site-level reporting accuracy.

Procedure

1. Identification of Device-Related Events
1.1 Investigators must report UADEs and device malfunctions to the sponsor within 24 hours.
1.2 Record in Device Event Log (Annexure-1).

2. Sponsor Evaluation
2.1 Assess severity, causality, and expectedness.
2.2 Document in Device Event Assessment Log (Annexure-2).

3. FDA and IRB Reporting
3.1 Submit UADE reports to FDA and all reviewing IRBs within 10 working days.
3.2 Record in UADE Reporting Log (Annexure-3).

4. Device Deviation Management
4.1 Document deviations from protocol or device instructions in Device Deviation Log (Annexure-4).
4.2 Investigate root causes and apply corrective actions.

5. Corrective and Preventive Actions (CAPA)
5.1 Develop CAPA for recurrent deviations.
5.2 Record in CAPA Log (Annexure-5).

6. Safety Database Management
6.1 Maintain validated device safety database with audit trails.
6.2 Perform quarterly reconciliation with clinical data.
6.3 Record in Database Reconciliation Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain UADE and deviation records for FDA inspections.
7.2 Conduct mock inspections documented in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• IDE: Investigational Device Exemption
• UADE: Unanticipated Adverse Device Effect
• FDA: Food and Drug Administration
• IRB: Institutional Review Board
• CRO: Contract Research Organization
• QA: Quality Assurance
• CAPA: Corrective and Preventive Action
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Device Event Log (Annexure-1)
2. Device Event Assessment Log (Annexure-2)
3. UADE Reporting Log (Annexure-3)
4. Device Deviation Log (Annexure-4)
5. CAPA Log (Annexure-5)
6. Database Reconciliation Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• 21 CFR 812 – Investigational Device Exemptions
• FDA – IDE Regulations and Guidance
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Device Event Log

Annexure-2: Device Event Assessment Log

Annexure-3: UADE Reporting Log

Annexure-4: Device Deviation Log

Annexure-5: CAPA Log

Annexure-6: Database Reconciliation Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP